Published in J Gen Intern Med on September 01, 2007
Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr Cardiol Rev (2009) 0.90
Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation (2005) 5.85
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart (2005) 1.57
MR findings in cardiac amyloidosis. AJR Am J Roentgenol (2006) 1.28
Value of cardiovascular magnetic resonance for determining cardiac involvement in systemic amyloidosis. Eur Heart J (2006) 1.07
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (2002) 6.11
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol (2002) 5.74
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med (2002) 5.42
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA (2013) 5.19
Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol (2003) 4.36
Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson (2013) 3.87
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol (2010) 3.50
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol (2008) 3.42
Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J (2004) 3.15
A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging (2003) 3.11
The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J (2007) 3.11
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging (2002) 2.95
Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol (2002) 2.87
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2008) 2.85
Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension (2002) 2.77
Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation (2012) 2.71
Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol (2011) 2.66
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol (2004) 2.59
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J (2006) 2.35
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.31
Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol (2009) 2.24
Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation (2006) 2.18
Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation (2002) 2.16
Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension (2002) 2.11
Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J (2003) 2.08
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Left ventricular wall thickness and the presence of asymmetric hypertrophy in healthy young army recruits: data from the LARGE heart study. Circ Cardiovasc Imaging (2013) 1.98
Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging (2003) 1.96
Regional thicknesses and thickening of compacted and trabeculated myocardial layers of the normal left ventricle studied by cardiovascular magnetic resonance. Circ Cardiovasc Imaging (2010) 1.94
Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation (2003) 1.91
Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility. Radiology (2002) 1.88
Accurate assessment of the arterial input function during high-dose myocardial perfusion cardiovascular magnetic resonance. J Magn Reson Imaging (2004) 1.86
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study. J Am Coll Cardiol (2004) 1.75
Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. Circulation (2011) 1.74
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. J Nucl Cardiol (2002) 1.68
Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol (2006) 1.67
Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet (2008) 1.67
Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica (2006) 1.66
Prognostic role of CMR in patients presenting with ventricular arrhythmias. JACC Cardiovasc Imaging (2013) 1.62
Prevalence of inferobasal myocardial crypts among patients referred for cardiovascular magnetic resonance. Circ Cardiovasc Imaging (2014) 1.61
Myocardial T2* measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. Magn Reson Med (2008) 1.60
The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail (2010) 1.57
Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol (2007) 1.55
Development of a novel optimized breathhold technique for myocardial T2 measurement in thalassemia. J Magn Reson Imaging (2006) 1.53
Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging (2005) 1.51
TakoTsubo cardiomyopathy: unravelling the malignant consequences of a benign disease with cardiac magnetic resonance. Heart Fail Rev (2015) 1.49
Integrated cardiac and vascular assessment in Takayasu arteritis by cardiovascular magnetic resonance. Arthritis Rheum (2009) 1.48
Coronary artery anomalies: assessment with free-breathing three-dimensional coronary MR angiography. Radiology (2003) 1.46
Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 1.46
New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions? JACC Cardiovasc Interv (2010) 1.46
MR Imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability. Cardiology (2003) 1.44
Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation (2005) 1.43
Black-blood T2* technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging (2007) 1.41
Variation in the lipoprotein lipase gene influences exercise-induced left ventricular growth. J Mol Med (Berl) (2006) 1.40
Myocardial T*2 measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. Magn Reson Med (2008) 1.38
Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation (2002) 1.36
Evidence for Marfan cardiomyopathy. Eur J Heart Fail (2010) 1.35
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging (2007) 1.34
Role of magnetic resonance angiography in the diagnosis of major aortopulmonary collateral arteries and partial anomalous pulmonary venous drainage. Circulation (2004) 1.33
Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging (2011) 1.32
Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol (2006) 1.30
Program of cell survival underlying human and experimental hibernating myocardium. Circ Res (2004) 1.27
Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. J Cardiovasc Med (Hagerstown) (2007) 1.26
In vivo diffusion tensor MRI of the human heart: reproducibility of breath-hold and navigator-based approaches. Magn Reson Med (2012) 1.21
The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation (2013) 1.19
Comparison of techniques for the measurement of left ventricular function following cardiac transplantation. J Cardiovasc Magn Reson (2002) 1.19
Measuring academic performance for healthcare researchers with the H index: which search tool should be used? Med Princ Pract (2012) 1.18
Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.15
Towards comprehensive assessment of mitral regurgitation using cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2008) 1.15
International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging (2010) 1.14
In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2014) 1.14
Interstudy reproducibility of quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2005) 1.13
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson (2014) 1.13
The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson (2006) 1.12
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging (2007) 1.10
CMR of ventricular function. Echocardiography (2007) 1.08
In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major. J Magn Reson Imaging (2013) 1.06
Complete Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI: Is it Really What We Should Be Doing? J Am Coll Cardiol (2015) 1.06
Reference right atrial dimensions and volume estimation by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 1.04
Quantification of regurgitant fraction in mitral regurgitation by cardiovascular magnetic resonance: comparison of techniques. J Heart Valve Dis (2004) 1.03
Doppler-echocardiographic assessment of pulmonary regurgitation in adults with repaired tetralogy of Fallot: comparison with cardiovascular magnetic resonance imaging. Am Heart J (2004) 1.03
Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson (2011) 1.03
Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart (2011) 1.03
Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2005) 1.03
Value of black blood T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 1.02
Direct comparison of myocardial perfusion cardiovascular magnetic resonance sequences with parallel acquisition. J Magn Reson Imaging (2007) 1.02
Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.02
Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson (2008) 1.02
Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size. J Magn Reson Imaging (2010) 1.00